123 related articles for article (PubMed ID: 20425764)
1. [Antisense against cancer?]].
Edris E; Möller AM; Oberhauser EM; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2010 May; 39(3):170-1. PubMed ID: 20425764
[No Abstract] [Full Text] [Related]
2. Antisense oligonucleotide therapy in cancer.
Stephens AC; Rivers RP
Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
[TBL] [Abstract][Full Text] [Related]
3. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
4. Hybridon and Aegera collaborate to develop antisense drug.
Expert Rev Anticancer Ther; 2002 Oct; 2(5):483-4. PubMed ID: 12382515
[No Abstract] [Full Text] [Related]
5. Liposomal antisense oligonucleotides for cancer therapy.
Siwak DR; Tari AM; Lopez-Berestein G
Methods Enzymol; 2004; 387():241-53. PubMed ID: 15172168
[No Abstract] [Full Text] [Related]
6. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
7. QC in antisense oligo synthesis.
Agris PF; Smith S; Fu C; Simkins SG
Nat Biotechnol; 2002 Sep; 20(9):871-2. PubMed ID: 12205500
[No Abstract] [Full Text] [Related]
8. Oligonucleotide pharmacotherapy: an antigene strategy.
Nagel KM; Holstad SG; Isenberg KE
Pharmacotherapy; 1993; 13(3):177-88. PubMed ID: 8321732
[TBL] [Abstract][Full Text] [Related]
9. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
Kim R; Emi M; Matsuura K; Tanabe K
Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapy in cancer.
Pawlak W; Zolnierek J; Sarosiek T; Szczylik C
Cancer Treat Rev; 2000 Oct; 26(5):333-50. PubMed ID: 11006135
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment.
Da Ros T; Spalluto G; Prato M; Saison-Behmoaras T; Boutorine A; Cacciari B
Curr Med Chem; 2005; 12(1):71-88. PubMed ID: 15638731
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
Olie RA; Zangemeister-Wittke U
Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
[TBL] [Abstract][Full Text] [Related]
14. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
15. Molecule of the Month. Mipomersem sodium.
Drug News Perspect; 2008 Oct; 21(8):464. PubMed ID: 19034352
[No Abstract] [Full Text] [Related]
16. [Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy].
Lebedeva IV; Staĭn SA
Mol Biol (Mosk); 2000; 34(6):1025-38. PubMed ID: 11186002
[No Abstract] [Full Text] [Related]
17. Evaluation of HIF-1 inhibitors as anticancer agents.
Semenza GL
Drug Discov Today; 2007 Oct; 12(19-20):853-9. PubMed ID: 17933687
[TBL] [Abstract][Full Text] [Related]
18. Potential use of radiolabeled antisense oligonucleotides in oncology.
Gauchez AS; Du Moulinet D'Hardemare A; Lunardi J; Vuillez JP; Fagret D
Anticancer Res; 1999; 19(6B):4989-97. PubMed ID: 10697501
[TBL] [Abstract][Full Text] [Related]
19. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of malignant diseases with synthetic oligonucleotides].
Rechavi G; Mandel M
Harefuah; 1992 Aug; 123(3-4):133-8. PubMed ID: 1516865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
